Brief: Revive Therapeutics applies to FDA for orphan drug designation for treatment of autoimmune hepatitis
27/09/2017 12:00
Sept 27 (Reuters) - Revive Therapeutics Ltd RVV.V :
* Revive Therapeutics applies to FDA for orphan drug
designation for treatment of autoimmune hepatitis
Source text for Eikon: ID:nMKW1sYpVa
Further company coverage: RVV.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure